Skip to content
,
Open navigation
or
Skip to contact information
.
Copyright © Inderes 2011 - present. All rights reserved.
Latest
Markets
Stock Comparison
Calendar
Research
Articles
inderesTV
Portfolio
Forum
Customer Companies
Settings
Collapse
Language
Copyright © Inderes 2011 - present. All rights reserved.
Log in
Log in
to receive notifications.
Claus Thestrup
Analyst
Coverage
InDex Pharmaceuticals Holding
Neodynamics
BoMill
Latest content
Showing
All content types
Analyst Comment
Recap on InDex Pharmaceuticals and update on PK results with Cobitolimod.
2023-03-29
by
Claus Thestrup
InDex Pharmaceuticals Holding
Analyst Comment
Zerion Pharma: A disruptive solution for poor drug solubility
2023-03-16
by
Claus Thestrup
Zerion Pharma
Analyst Comment
NeoDynamics: Management elaborates on options for long-term financing
2023-03-16
by
Claus Thestrup
Neodynamics
Analyst Comment
Introduktion til nyt dansk biotekselskab Pharma Equity Group
2023-03-06
by
Claus Thestrup
Pharma Equity Group
Analyst Comment
Qlife - Soft-launch of their first CRP biomarker test under the Egoo Health brand
2023-03-04
by
Claus Thestrup
Qlife Holding
Analyst Comment
Interview with CEO Magnus Corfitzen from Ascelia Pharma on latest data on the SPARKLE study.
2023-03-03
by
Claus Thestrup
Ascelia Pharma
Analyst Comment
BoMill appoints new Head of Sales
2023-03-01
by
Claus Thestrup
BoMill
Analyst Comment
NeoDynamics is investigating options to raise long-term capital to enable commercialization of NeoNavia in the US
2023-03-01
by
Claus Thestrup
Neodynamics
Analyst Comment
InDex Pharmaceuticals will attend the ECCO 2023 congress
2023-02-28
by
Claus Thestrup
InDex Pharmaceuticals Holding
Analyst Comment
Interview with CEO Ulrich Krasilnikoff and CSO Andreas Kjær on highlights from FY 2022 and update on pipeline
2023-02-28
by
Claus Thestrup
Curasight
Load more